A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants

StatusActive, Not Recruiting
PhasePhase 2
SponsorAbbVie
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Enrollment target: estimated 80 to confirmed 84
    • Study completion date: Nov 2026 to Oct 2026
    • Site details revised at 5 of 5 sites
    • Eligibility criteria expanded, about 5 words
  2. Recruitment opened
    • Trial sites expanded: 0 → 5 locations
    • Primary completion date: Nov 2026 to Oct 2026
    • Start date changed from estimate of Jul 28, 2026 to Jul 22, 2026
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AbbVie
349 trials monitored
See 27 trials at risk
The objective of this study is to evaluate the safety and efficacy of AGN-151586 for the treatment of moderate to severe forehead lines (FHL) in adult participants.
Trial Details
NCT Number NCT07730554
Lead Sponsor AbbVie
Conditions
(from sponsor)		 Forehead Lines
Enrollment 84 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov